02:23 , Jun 29, 2019 |  BioCentury  |  Finance

New fund to expand Anlong’s tool kit for early stage deals

Anlong Fund is seeking to raise $100 million for its first dollar-denominated fund that would be nearly double the size of the the Chinese firm’s two renminbi funds. The goal is to sidestep regulatory red...
06:04 , Jun 10, 2019 |  BC Extra  |  Company News

With industry's growing kidney momentum, Everest begins building kidney portfolio

Everest Medicines added its first therapy to a planned renal portfolio on Monday through a deal with Calliditas. The therapy, Nefecon (PL-56, Nefigan), is in the Phase III Nefigard trial to treat IgA nephropathy. It...
21:29 , May 10, 2019 |  BC Extra  |  Company News

Management tracks: Roche veteran Chen joins Everest, CBC Group; plus G1, Rani

Everest Medicines Ltd. (New York, N.Y.) hired Wende Chen as chief commercial officer. He will also serve as an operating partner at CBC Group (formerly C-Bridge Capital), the company's founding investor. Chen was VP of...
20:29 , Apr 29, 2019 |  BC Extra  |  Company News

With Immunomedics ADC deal, Everest bolsters cancer pipeline

Undeterred by a complete response letter issued by FDA in January for Immunomedics' sacituzumab govitecan, Everest obtained the therapy's rights in several Asian territories, making the antibody-drug conjugate Everest's most advanced oncology asset thus far....
20:04 , Apr 25, 2019 |  BC Innovations  |  Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for...
22:05 , Sep 25, 2018 |  BC Extra  |  Company News

Everest adds another antibiotic to pipeline through VenatoRx deal

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) will receive exclusive rights from VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) to develop and commercialize VNRX-5133 in combination with cefepime. The deal covers Greater China, South Korea and Southeast Asia...
21:29 , Jul 20, 2018 |  BC Extra  |  Financial News

Ascletis sets terms for Hong Kong IPO

In a regulatory filing , antiviral company Ascletis Pharma Inc. (Hangzhou, China) revealed terms of its planned IPO on the Hong Kong exchange. The company hopes to raise HK$2.7-HK$3.6 billion ($342.7-$456.9 million) through the sale...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Financial News

I-Mab raises $220M in series C

I-Mab Biopharma (Shanghai, China) raised $220 million June 29 in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past...
23:14 , Jun 29, 2018 |  BC Extra  |  Financial News

I-Mab continues trend of large Chinese-led venture rounds

I-Mab Biopharma (Shanghai, China) raised $220 million Friday in a series C round led by Hony Capital, making it at least the fourth $200 million-plus VC round led by Chinese investors in the past two...
18:28 , Jun 29, 2018 |  BC Week In Review  |  Financial News

C-Bridge leads Nuance's series B

Nuance Biotech (Shanghai) Co. Ltd. (Shanghai, China) raised $20 million in a series B round led by C-Bridge Capital. Nuance is eligible to receive an additional $15 million from C-Bridge for acquiring new products. Nuance...